Abstract: A number of biomarkers are used clinically and many protein-based assay methods are available. Improvements in the method to utilize specifi c antibodies have led to remarkable progress in clinical diagnosis using biomarkers. Proteomics studies to identify better biomarkers have been performed worldwide by using a protein-based comprehensive method. The detection rate of conventional biomarkers can not improve further. Now is a time that a breakthrough is needed. We previously proposed mRNA, which is circulating in the body, as a novel material for biomarkers. mRNA is an unexpectedly useful molecule, not only because it can detect genes with a low expression level in protein, but also because it can detect the expression from non-coding RNA precursor genes or gene products with limited secretion from the cells. Circulating mRNA has been thought to be unstable in blood containing RNase. We confi rm that mRNA remains at the same level for 24 hours after blood sampling. Unlike DNA, the RNA molecule can refl ect events in the human body which occurred within a day, resulting in an early diagnosis of diseases. We report the possibility to detect and quantify cancer-derived mRNAs circulating in human vessels. We introduce the detection of serum mRNA as a useful biomarker of human malignancies.
Background of Circulating Nucleic Acids
Since the discovery of circulating nucleic acids in plasma in 1948, many diagnostic applications have emerged. Small amounts of circulating nucleic acids (CNA) are present in the plasma of healthy individuals. Increased levels of plasma CNA have been reported in a number of clinical disorders such as cancer, stroke, trauma, myocardial infarction, autoimmune disorders and pregnancy-associated complications. CNA has received special attention because of its potential application as a non-invasive, rapid and sensitive tool for molecular diagnosis and monitoring of the diseases, and the prenatal diagnosis of fetal genetic diseases. A simple blood test for cancer detection has been the quest of many researchers in particular. Recently, CNA instead of a protein has been used in practical diagnosis. Cell-free circulating nucleic acids in plasma/serum derived from tumor tissues, have received much interest. Although it is well known that higher concentrations of DNA (deoxyribonucleic acid) are present in the plasma of cancer patients sharing some characteristics with DNA of tumor cells (1, 2, 3, 4) , it has been reported that mRNAs detected in blood refl ects the early event in a clinical condition (5) . Since RNA (ribonucleic acid) in plasma/serum may be a suitable source for the development of noninvasive diagnostic, prognostic and follow-up tests for cancer, this discovery has provided us with very promising assays useful for early detection of malignancies.
Circulating RNA as Diagnostic Source
A recent development in this new fi eld is the identification of tumor-related RNA in the plasma/serum of cancer patients (6) . These include tyrosine kinase mRNA (7) , telomerase components (8, 9) , the mRNAs that are encoded by different tumor-related genes (10, 11, 12, 13, 14) , and viral mRNA (14) . As more RNA than DNA markers can be detected in the circulation of cancer patients, an assay using RNA markers produced higher sensitivity than other conventional assays. In one study, two telomerase markers of breast cancer yielded 44% positive rates (8) . However, telomerase RNA seems to be a promising marker as it can be detected even in the serum of patients with small, undifferentiated breast cancers without any metastatic lesions. Dasi et al. showed that circulating telomerase RNA is a sensitive marker, using real-time reverse transcription-polymerase chain reaction (real time RT-PCR) (9) . In their study, 8 of 9 plasma samples from colorectal cancer patients and 9 of 9 plasma samples from patients with lymphoma tested positive for human telomerase reverse transcriptase. The plasma samples of all 10 healthy individuals were negative.
Methods
To detect a transcript of interest in cell-free serum, quantitative real-time RT-PCR was performed by using 1 µl of RNA extract and 2 µl of SYBR Green I (Roche, Basel, Switzerland) in a One
Step RT-PCR kit (Qiagen, Tokyo, Japan) using LightCycler with reproducibility. After blood sampling, RNA was extracted with DNase treatment after three steps of centrifugation of serum as previously reported with a few modifications mainly including a precise gravity control of centrifugation to obtain cell-free serum and mRNA quantifi cation using optimized primer set (INTEC Web and Genome Bioinformatics, Tokyo, Japan) (8, 16) . Other minor modifi cations are as follows. RNA from 200 µl of serum was dissolved in 200 µl of water. Quantitative RT-PCR was performed by using 1 µl of RNA extract and 2 µl of SYBR Green I (Roche, Basel, Switzerland) in a One Step RT-PCR kit (Qiagen, Tokyo, Japan). RNA in serum was extracted by using the same volume of serum and dried up to 20-fold concentration. RNAs from tissues were extracted using TRIzol Reagent according to manufacture's instructions (Invitrogen Corp., Carlsbad, CA, U.S.A.). RT-PCR consisted of an initial incubation at 50 °C for 30 min followed by a 12-min incubation at 95 °C, then 50 cycles at 95 °C (0 s), 55 °C (10 s), and 72 °C (15 s) , and a 20 second melting at 40 °C. The dynamic ranges of real-time PCR analysis for mRNA of interest were more than approximately 5 to 10 copies in this assay. We could therefore exclude the possibility of false negative results in serum samples from patients and controls. To examine signifi cant clinicopathological fi ndings affecting mRNA and other markers, the difference among diseases and stratifi ed categories in each clinical parameter was statistically evaluated. Tumors, tumor size, number of tumors, histological fi ndings including differentiation degree of tumors, clinical staging, and the presence of metastasis were analyzed. Correlations among biomarkers were calculated using Pearson's relative test. To assess the accuracy of diagnostic tests, the matched data sets (patients with reference diseases or healthy individuals and those with malignancies) for biomarkers were analyzed using receiver operator characteristic (ROC) curve analysis. This assay demonstrated a strong linear relation between copy number and PCR cycles using RNA controls (r 2 Ͼ 0.99) (Fig. 1A) . A correlation of mRNA between malignant tissue and serum was analyzed to examine whether serum mRNA is derived from the original tissues by both paired t test and Spearman's test. Optimal predictive cut-off values and the sensitivity/specifi city for mRNA expressions, and positive predictive value (PPV)/ negative predictive value (NPV) during carcinogenesis were calculated. All the primers were optimally designed (INTEC Web and Genome Informatics corp., Tokyo, Japan).
Biomarkers in Hepatocellular Carcinoma
Introduction HCC is a highly fatal cancer that affects approximately half a million people worldwide (17, 18) . The incidence of HCC has been rising rapidly and this increase has generated concern among clinicians, researchers and policy makers. Major risk factors of HCC include hepatitis C virus (HCV), hepatitis B virus (HBV), nonalcoholic steatohepatitis (NASH) and heavy alcohol consumption. Development of HCC is generally thought to depend on the rapid and long-term repeated cell turnovers. This indicates that HCC expands clonally from the hepatocytes which have been suffering intense infl ammation for a long duration, causing senescence. It would be advantageous to detect the evidence of clonal occurrence of HCC at an early stage using a newly developed modality.
Tumor markers for HCC
AFP has been used as a serum marker for HCC in humans for many years and has a sensitivity of 39%-65% and specifi city of 76%-94% (19) . However, the detection rate can be improved using ultrasonography (US) (20) . Several biomarkers such as DCP, AFP-L3 (21), human hepatocyte growth factor (HGF), and insulin-like growth factor-1(IGF-1) are promising, but none of these markers have been validated for clinical use compared to AFP. There is an urgent need for novel biomarkers for the detection of early-stage HCC (22) . The marker should be specifi c for HCC, enabling the detection of HCC at an early stage, easily measured and the test should be reproducible, minimally invasive and acceptable to patients and physicians (23) . Among biomarkers identifi ed at this stage, DCP and AFP-L3 have been most extensively studied and seem to be promising. DCP has a sensitivity of 28% to 89% and specifi city of 87% to 96%. AFP-L3 has a sensitivity of 36% to 96% and specifi city of 89% to 94%. Most of these markers are measured by enzyme immunoassay (EIA) to detect proteins due to the advantage of its stability. 
Figure. 1 (A)
In each quantitative assay, a strong linear relation was demonstrated between copy number and PCR cycles using RNA controls for concentration (r = 0.99 for hTERT mRNA: left; r = 1.0 for EGFR mRNA: right). The dynamic ranges of real-time PCR analysis for hTERT mRNA and EGFR mRNA were more than approximately 5~10 copies in this assay and we were able to exclude the possibility of false negativity in serum samples from patients and controls. Control hTERT mRNA for standardization was generated using T7 RNA polymerase in pLIXN-hTERT cDNA kindly provided from Dr. H. Tahara (Hiroshima University, Japan) and another control EGFR mRNA was similarly generated using pCRII-TOPO-EGFR (Invitrogen Japan K.K, Tokyo, Japan) retrofi tted from pME18SFL3-EGFR purchased as FLJ cDNA clone commercially (TOYOBO, Tokyo, Japan). (B) A dot plot represents the signifi cant correlation of (left) hTERT mRNA level in serum in lung cancer tissues in 23 patients and of (right) EGFR mRNA level in serum in lung cancer tissues in 9 patients. Only a minority of the cases that were positive for mRNA in the tissue specimens (n = 23 for hTERT, n = 9 for EGFR) is included in this analysis. Positive is defi ned as "above the predictive cut-off values for both mRNAs obtained from this study in 112 lung tumors and 80 healthy individuals". These data were analyzed by the paired t test (p Ͻ 0.01 for both) and non-parametric Spearman's test (p = 0.021 for hTERT mRNA, p = 0.002 for EGFR mRNA, respectively). The data were evaluated by logarithm of quantifi cation.
Application of the hTERT mRNAs in blood for diagnosis
The telomerase enzyme complex has two major subunits and its expression is mainly regulated by a catalytic subunit (human telomerase reverse transcriptase, hTERT) (2). Since many kinds of mRNAs could be found in the plasma and serum of healthy individuals and cancer patients (3), it has been suggested that the detection of cancerrelated gene expression in the serum is very useful for the diagnosis and follow-up of patients. The hTERT mRNA or endogenous RNA component derived from cancer cells did not seem to be detectable in serum due to its instability by RNase (ribonuclease) in serum. However, since RNAs in serum are stable at most for 24 hour after drawing blood (24, 25) , it has been suggested that they can even be detected in blood by a narrow margin (7, 26) . hTERT mRNA can be detected in serum from breast cancer patients and its maximum sensitivity and specifi city were at most 40% and 100% respectively (8) . We previously reported that approximately 88% was qualitatively positive for the detection of HCC-derived RNA in serum (16) , indicating that serum RNA can be applied for the diagnosis of other cancers as well as HCC. We singled out hTERT mRNA as the most appropriate molecule for cancer diagnosis. In this context, we focused on HCC, since hTERT mRNA is gradually increased during the multi-step process of hepatocarcinogenesis (27) . ROC curve analyses showed that the sensitivity/specifi city of hTERT mRNA for HCC were 88.2%/68.7% (Fig. 3A) . At that time, optimal predictive cut-off values for both mRNA expressions were 12 500 copies/0.2 ml and 3000 copies/0.2 ml, respectively. In the assay, the sensitivity/specifi city in each tumor marker during hepatocarcinogenesis is shown in Table 2B . and des-γ-carboxy prothrombin (DCP). However, the diagnostic potential of these markers cannot surpass abdominal ultrasonography (US) as modalities to detect small HCC in the early stage. There is a need to develop additional sensitive markers to improve the early detection of HCC. We introduce a newly developed quantitative method for detecting serum hTERT mRNA, which has a clinical significance in HCC diagnosis.
Materials
In 154 subjects, including 64 with HCC, 20 with liver cirrhosis, 20 with chronic hepatitis, and 50 healthy individuals, we measured serum hTERT mRNA using the newly developed realtime quantitative RT-PCR with SYBR Green I. Briefly, we examined its sensitivity and specificity in HCC diagnosis, clinical significance in comparison with other conventional tumor markers than mRNAs, and its correlations with the clinical parameters by using multivariate analyses and Friedman's test. Serum hTERT mRNA showed higher values in patients with HCC than in those with chronic liver diseases. hTERT mRNA expression was demonstrated to be independently correlated with clinical parameters such as tumor size (p Ͻ 0.001), number (p Ͻ 0.001) and differentiation degree (p Ͻ 0.001). The sensitivity and specifi city of hTERT mRNA in HCC detection were 88.2% and 70.0% respectively. hTERT mRNA proved to be superior to AFP mRNA (71.6 and 67.5), AFP (69.3 and 60.0) and DCP (81.5 and 63.5), respectively (Table 2-A). Importantly, hTERT mRNA in serum was correlated with that in HCC tissue.
Serum hTERT mRNA is a novel and available marker for HCC detection. We are conducting a large-scale study with approximately 500 patients on the feasibility of HCC diagnosis. This method will be suitable for a number of hTERT-positive malignancies, and for the quantifi cation of the expression of genes of which protein products are weakly expressed. 
Biomarkers in lung cancer (non small cell lung cancer: NSCLC)

Introduction
Lung cancer is the leading cause of malignancyrelated mortalities (28) with little change in the survival rates over the past two decades (29) . Nonsmall cell lung cancer (NSCLC) now accounts for about three-quarters of all cases of lung cancer (30) . Most patients die of progressive metastatic disease despite the development of new therapeutic strategies and advances in surgical treatment. Serum tumor markers are non-invasive diagnostic tools for malignant tumors and they are commonly used for the screening of cancer and as an indicator of the treatment-effect. In small cell lung cancer (SCLC), neuron-specifi c enolase (NSE), and progastrin-releasing peptide (proGRP) are effective markers. In NSCLC, carcinoembryonic antigen (CEA), squamous cell carcinoma related antigen (SCC) and cytokeratin 19 fragment (CYFRA 21-1) are commonly used for screening. At least one marker among CEA, SCC and CYFRA is positive in approximately 70% of patients with NSCLC (30) . According to the histological category, the positive rates of CEA and CYFRA are high in adenocarcinoma (ADC) patients, and the positive rates of CYFRA and SCC are high in squamous cell carcinoma patients. Although the standard diagnostic procedures such as X-ray examinations, conventional tumor markers and bronchial lavage (BL) are important for the detection of lung cancer, they are still not sensitive enough to detect lung cancer at an early clinical stage. Tyrosine kinase activity of epidermal growth factor (EGFR) promotes tumor cell proliferation, cell survival, angiogenesis, invasion, and metastasis, and its specifi c inhibition by gefi tinib, a synthetic anilinoquinazoline, has been demonstrated (32) . EGFR is expressed in 20% to 80% of tissue specimens of NSCLC (33), but its expression has been observed in progressive type of SCLC (34) . EGFR may therefore be a potential molecule for diagnosis or a good target that determines responsiveness to EGFR-targeted therapies (35) . Some groups have reported that cell-free circulating hTERT mRNA in plasma can be detected in 12% of patients with lung cancer (NSCLC) (5), suggesting that hTERT mRNA detected in blood may be applicable for lung cancer as a diagnostic vehicle.
This study on pulmonary malignancy also demonstrates the clinical usefulness of hTERT mRNA, especially when combined with EGFR mRNA as a novel tumor marker in primary lung cancer for early detection and diagnosis. This method would be useful for patients or ethnic groups in which drugs targeting EGFR in lung cancer are thought to be effective. (Table 3 ). The mean age of the patients was 63 years (range 22 to 90 years). The patients were diagnosed based on serological examinations, chest X-rays, (helical) computed tomography (CT), chest and brain magnetic resonance imaging (MRI), cytological examinations, and transbronchial, percutaneous, and thoracoscopic lung biopsies. The fi nal diagnosis was made using surgically resected specimens for pathology. Patient demographics, diagnostic tumor size, number of tumors, tumor markers including CEA, SCC, CYFRA, proGRP, NSE, TPA, SLX, history of smoking (estimated by Pack-Year index), the presence of metastasis or recurrence, and clinical stage (IA~IV) were evaluated. Twenty-seven healthy individuals including 12 females (range 22 to 90 years old: mean age 58 years) served as controls. To examine any change in gene expression in serum before and one month after surgical treatment in the same patients and to examine their significance as tumor markers, we quantified hTERT mRNA and EGFR mRNA expression in 9 patients with lung cancer. Control EGFR mRNA was generated using pCRII-TOPO-EGFR (Invitrogen Japan K.K, Tokyo, Japan) retrofi tted from pME18SFL3-EGFR and purchased as a FLJ cDNA clone (TOYOBO, Tokyo, Japan).
Patients and sample collection
mRNA quantifi cation and clinical parameters
In each quantitative assay, a strong linear relation was demonstrated between copy number and PCR cycles using RNA controls for concentration (r 2 Ն 0.99 for hTERT mRNA and EGFR mRNA; Fig. 1A) . The copy numbers of hTERT mRNA (p Ͻ 0.01) and EGFR mRNA (p Ͻ 0.01) were signifi cantly higher in the lung cancer patients than in the healthy individuals. Pearson's relative 
Statistical analysis and ROC curve analysis
Clinicopathological fi ndings that were analyzed by one-way ANOVA showed signifi cant relations to hTERT and EGFR expression in the serum (Table 3) (Table 4) . On the other hand, the specifi city of CEA, SCC, CYFRA, EGFR mRNA and hTERT mRNA was 74.4%, 58.3%, 74.2%, 62.5% and 72.5%, respectively. The positive predictive value (PPV) and negative predictive value (NPV) of hTERT mRNA were the highest of the tumor markers examined. copies/0.2 ml, respectively. The cut-off values of hTERT mRNA combined with EGFR mRNA, which did not signifi cantly correlate with each other, were calculated as the summation of both measurements prior to the logarithm of quantifi cation, and showed no relative signifi cance to each other. The combination of hTERT and EGFR mRNA was superior to any of the other tested serum markers used for isolation.
Correlation of hTERT mRNA and EGFR mRNA detection in paired serum and tumor tissue samples
The copy number of hTERT mRNA in serum was signifi cantly correlated with that in cancer tissue (p Ͻ 0.05). The copy number of EGFR mRNA in the serum was signifi cantly related to that in the cancer tissue specimens (p Ͻ 0.01), Fig. 1B ). The data suggest that both RNAs in the serum are derived from lung cancer tissue specimens.
Evaluation of serum hTERT quantifi cation as a tumor biomarker
The quantitative decrease in hTERT mRNA one month after surgical treatment, compared with that before the treatment shown in Fig. 4A , suggests that hTERT mRNA is a useful biomarker which can be applied to cancer patients. Although EGFR mRNA tended to decrease after the treatment, this decrease was not statistically signifi cant.
Summary
We attempted to clarify its clinical signifi cance as a biomarker for lung cancer. In 89 patients with lung cancer and 27 individuals without, we measured serum hTERT mRNA and epidermal growth factor receptor (EGFR) mRNA levels, using a quantitative one-step real-time RT-PCR assay. We examined its sensitivity and specifi city in lung cancer diagnosis, its clinical signifi cance in comparison with other tumor markers, and its correlation with the clinical parameters using multivariate analyses and the correlation relative test. The sensitivity/specifi city values are 71.8%/72.5% for hTERT mRNA, 60.8%/62.5% for EGFR mRNA, 48.8%/74.2% for CYFRA, 58.9%/58.3% for SCC, and 40.1%/74.4% for CEA. In the diagnostic assessment of sensitivity and specifi city, hTERT mRNA (0.718/0.725) was identifi ed as the most excellent tumor marker.PPV: positive predictive value, NPV: negative predictive value. Sensitivity, specifi city,p value, and PPV/ NPV of hTERT + EGFR mRNA were calculated, based on the summation of each logarithmic cut-off values.
malignancies to diagnose and assess the clinical stage and effects of treatments.
Biomarkers in Gynecologic Malignancies
Introduction
Ovarian cancer is the fi fth most common cancer in women. Despite the fact that it is highly curable if diagnosed early, ovarian cancer kills more women each year than all other gynecologic malignancies (37) . There are no proven methods of prevention, and it is often a rapidly progressive and fatal disease. The only validated marker for ovarian cancer is CA125, which is detectable in the serum of more than 80% of women with ovarian cancer. In contrast, cervical cancer is the third leading cause of cancer death in women. Over half a million new cases are diagnosed every year worldwide. The most common histological type of cervical cancer is squamous cell carcinoma which accounts for more than 80% of all cervical cancers. An increasing number of reports indicate that other factors are involved along with human papilloma virus (HPV) to induce cervical carcinogenesis. A routinely used biomarker for advanced cervical cancer is SCC, which is detectable in the serum of less than 50% of women with cervical cancer. CA125 and SCC are reliable only in monitoring the response to treatment or recurrence, but not as a diagnostic or prognostic marker (38) . Thus, there is considerable interest in identifying molecular diagnostic and prognostic indicators to guide treatment decisions.
It is well known that one of the carcinogenic biomarkers, human telomerase reverse transcriptase (hTERT) (39, 40) , is not only expressed in mild dysplastic lesions in cervices (41) , but is also often expressed in gynecological malignancies. Positive is defi ned as "being above the predictive cut-off values for both mRNAs obtained from this study in 89 lung tumors and 27 healthy individuals". These data for hTERT mRNA were analyzed by Wilcoxon's test and the paired t test (p < 0.028 and p = 0.035, respectively). The data are evaluated by a logarithm of quantifi cation. (B) The quantifi cation of both mRNAs in the serum before, during, and 7 days after any treatment including chemotherapy or surgical treatment is stratifi ed into three groups. The data are evaluated by a logarithm of quantifi cation. hTERT mRNA expression among the three groups was evaluated by the paired t test (*p < 0.05). N.S. means not signifi cant.
Patients and sample collection A total of 176 consecutive patients (47 patients with ovarian cancer, 63 with uterine cancer, 2 with other gynecologic cancer, 2 with border lesions, and 62 with benign diseases) that were admitted to Tottori University Hospital between December 2003 and January 2005, were enrolled in this study.
Of the patients with benign disease, 41 had benign ovarian diseases including 11 with an ovarian dermoid cyst, 4 had endometriosis in the ovary, 13 had an ovarian cyst and 21 had benign uterine diseases including 1 patient with invasive hydatidiform mole, 4 with adenomyosis of the uterus, 14 with uterine myoma and 2 with uterine prolapse. Twenty healthy patients served as controls. The mean age of the patients was 55 years (range 18 to 85 years). CA125 (ChemilumiACS-CA125II, Bayer Japan, Tokyo) and SCC (SCC RIAbeads, SRL, Tokyo, Japan) in the serum were measured in routine laboratory tests. Human papilloma virus (HPV) was not examined for uterine lesions. The patients were diagnosed by chief complaints, ultrasonography, computed tomography (CT), CA125 or SCC, cytology or biopsy under internal examination, histological examination after laparoscopy or surgical therapy. The clinicopathological fi ndings, gender, age, etiology, histological fi ndings, CA125 for ovarian disease, SCC for uterine disease, tumor size, clinical staging, and presence of recurrence were evaluated.
mRNA quantifi cation and clinical parameters
According to this quantitative assay, the copy numbers of hTERT mRNA were signifi cantly higher in the gynecologic cancer patients than in the healthy individuals (p Ͻ 0.01, each). Clinicopathological fi ndings showed signifi cant relations to hTERT mRNA in the serum (Table 5) . By multivariate analysis, the hTERT mRNA level was signifi cantly correlated with age, the presence of cancer, ovarian disease in organs, ovarian malignancies, tumor size, and CA125 (p Ͻ 0. To examine the sensitivity and specifi city of tumor markers for diagnosis of gynecologic malignancies, ROC curve analysis showed the sensitivity/specifi city of hTERT mRNA for gynecologic malignancies to be 74.4%/74.1% (data not shown). For ovarian malignancies, area under the curve (AUC) of hTERT mRNA and CA125 were 90.9% and 83.3%, respectively, and the sensitivity/specificity of hTERT mRNA in ovarian cancer is 95.0%/90.0% (Fig. 3C) . The sensitivity/specifi city of hTERT mRNA and SCC in uterine cancer is 70.1%/81.5% and 50.0%/67.5% respectively. On the other hand, the sensitivity/specifi city of hTERT mRNA and CA125 in ovarian cancer is 100%/76.5% and 100%/75.5% respectively. For uterine malignancies, AUC of hTERT mRNA and SCC were 72.2% and 30.6% (Fig. 3D) , respectively. The optimal cut-off values for hTERT mRNA and EGFR mRNA were calculated as 10 4.1 copies/0.2ml and 10
2.99 copies/0.2 ml, respectively.
Evaluation of serum hTERT quantification as a tumor biomarker
All patients were stratifi ed into three categories based on the timing of blood sampling (before, during, and after therapy) and the therapeutic effect such as anti-tumor agents or surgical treatment was estimated by a t test. Although there was no correlation between before and during blood sampling, hTERT mRNA signifi cantly decreased after therapy, compared with before and during the therapy (p Ͻ 0.05, each) (Fig. 4B ). This suggests that the measurement of hTERT may be useful for the evaluation of a therapeutic effect. In uterine malignancies, hTERT mRNA and SCC were signifi cantly useful biomarkers to evaluate therapeutic effect (p = 0.001 and p = 0.026, respectively). In ovarian malignancies, hTERT mRNA and CA125 were signifi cantly useful for the diagnosis of cancer (p = 0.001 and p = 0.043, respectively). The copy number of hTERT mRNA in serum was signifi cantly correlated with that in cancer tissue (p = 0.028 in Wilcoxon's test, p = 0.035 in the paired t test).
Summary
We attempted to elucidate the diagnostic evaluation of serum hTERT mRNA for gynecologic malignancies with our method. the diseases. hTERT mRNA is useful for diagnosing gynecologic cancer and is superior to conventional tumor markers. Therefore, serum hTERT mRNA is a novel and available biomarker for gynecologic malignancies.
Discussion
In a subsequent quantitative study, we have improved the sensitivity to detect the instable nucleotides in blood by removing cellular proteins and minimizing the contamination of cellular nucleic acids in serum and a primer set which can amplify hTERT mRNA effi ciently (35) . Furthermore, the correlation between tumor tissue and serum in terms of hTERT mRNA was demonstrated in Figure 1B , suggesting that hTERT mRNA detected in serum is derived from tumor cells. AFP is widely used as a reliable marker of HCC, not in earlier stage but in advanced stage (42) . Since HCC recurs repeatedly and polyclonally due to biological characteristics even after any treatments, the monitoring of serum hTERT mRNA might make it possible to diagnose the recurrence earlier.
In this respect, we prospectively have to conduct a follow-up study after the treatment of HCC (manuscript in preparation). hTERT mRNA expression was found to be closely associated with a well to moderate degree of differentiation of HCC. Nakashio et al. previously reported a signifi cant correlation between HCC differentiation and telomerase expression (43) . The results in the present study confi rmed their fi ndings. hTERT mRNA showed more sensitivity and specifi city compared with AFP mRNA in HCC diagnosis. AFP mRNA did more sensitivity and specifi city compared with AFP level (5). The higher specifi city of hTERT mRNA may be related to the fact that AFP mRNA is produced in HCC cells and injured hepatocytes. However, hTERT is produced mainly in HCC cells. Waguri et al proved that hTERT mRNA in circulating cancer cells, derived from HCC tissues, can be detectable by using a cell-sorting system that they developed. The authors indicated that HCC cells released from the original HCC were within 10 mm in size (44) and suggested that the value is consistent with the result of the mRNA detection method. Our studies suggest that quantifi cation of hTERT mRNAs in serum has diagnostic implications for NSCLC and ovarian cancer as well as HCC. We will evaluate the correlation between prognosis and hTERT mRNA (45) , and assess the availability of hTERT mRNA in other hypervascular cancers by comparing hTERT mRNA with other tumor markers. We are performing a largescale study with more than 500 patients to confi rm our results for the monitoring and detection of HCC. Since our assay is difficult to perform manually, we are developing an automatic, concise and rapid diagnostic apparatus with a reagents kit to be introduced into clinics, even at the primary care level. In the diagnostic fi eld of medicine, current patent laws involved in intellectual property rights are limiting diagnostic progression. This method will be suitable for the diagnosis of a number of hTERT-positive malignancies and for cancer-specifi c RNA genes or other genes showing weak protein levels. The systemic introduction of this assay into the primary care level can be expected in the near future.
In pulmonary and gynecological malignancies, we suggest that the correlation with response/survival may be more evident if this more sensitive mRNA-based detection assay is used. The induction of a combination of hTERT mRNA and EGFR mRNA into the early diagnosis of lung cancer may improve the follow-up of patients. Since the data shows that hTERT and EGFR mRNA levels are associated with previously detected lung cancers, it does not demonstrate whether the method is suffi ciently robust for early detection. However, the evaluation of hTERT mRNA combined with EGFR mRNA may be a useful biomarker to diagnose and assess the clinical stage and effect of treatments in patients with lung cancer. Further case-control studies should be planned to evaluate both longterm and former smokers who do not have lung cancer. hTERT mRNA is useful in the diagnosis of gynecologic cancers as well and is superior to conventional tumor markers. Therefore, serum hTERT mRNA is a novel and available biomarker for gynecologic malignancies.
Investigations into other diseasespecifi c mRNAs and the clinical signifi cance
In other malignancies such as thyroid cancer and pancreatic cancer (in preparation), this assay has been applied (manuscript under preparation for publication). We are investigating other diseasespecifi c mRNAs as biomarkers to be applied in the clinic or in primary care. The fi eld of medical care we are engaged in is the diagnosis of intractable disease (Table 6 ). It is necessary to fi nd improved mRNA such as hTERT, compared to Positron Emission Tomography (PET), as a diagnostic vehicle. We are studying infl ammatory diseases such as fulminant hepatitis (46) or acute respiratory distress syndrome (in preparation), and lifestyle-related diseases, autoimmune diseases, and disease from gene dysfunction which are difficult to diagnose or estimate the clinical condition.
Conclusion
Additional diagnostic methods (e.g. imaging), or combination of other biomarkers would be still needed to determine the type and location of the tumor. In our investigations, circulating mRNA is a very sensitive molecule to detect diseases in organs with rich blood fl ow or systemic infl ammatory disease. The presence of acute phase diseases, including cancer progression, could be detected if mRNA is tested for within one day of blood sampling. However, this assay has a limitation. It can be infl uenced by organs with rich blood fl ow such as the liver. The disease of interest may be masked, for example in patients suffering from progressive liver disease. Based on these actual circumstances, it is likely that further developments over the next few years in the fi eld of circulating RNA will provide us with new diagnostic and monitoring possibilities. Table 6 . Application of this assay for malignancies and other diseases. 
Application for malignancies
